RP1 Combined With Nivolumab in Advanced Anti-PD-1-Failed Melanoma (IGNYTE)
{{output}}
Purpose: Effective treatment options for melanoma after immune checkpoint blockade failure are limited. RP1 (vusolimogene oderparepvec) is an HSV-1-based oncolytic immunotherapy, here evaluated in combination with nivolumab in an... ...
